Recently the Pharmaceutical Benefits Advisory Committee (PBAC) announced the outcome of their July Meeting. The MG community were keenly waiting to hear the PBAC Outcomes as two new medications, Raviluzimab and Zilucoplan, had been reviewed. Regrettably both medications received a ”Not Recommended” verdict. The PBAC did recognise the high clinical need for effective therapies for gMG.
Whilst extremely disappointing it is not the end of the process. Alexion assures the MAA that they are committed to working with the PBAC alongside the MG Clinical and patient communities to bring access at the earliest opportunity to their treatment.
Both Pharmaceutical companies (Alexion and UCB) will resubmit in 2025.
Please read below for a statement from Libby Noble at Alexion.
Patient Advocacy Director, Libby Noble told us: “We had hoped for a different outcome and we understand it’s both upsetting and frustrating to many who struggle with this condition and especially to those who took the time to share their views to the PBAC. We want to extend our sincere gratitude to MAA and the MG community for their invaluable input and support throughout this process. On a positive note, we are pleased that the PBAC recognised the high clinical need for effective therapies for MG, particularly in patients who are not responding to or are unable to use existing therapies, and for those with refractory disease. That recognition is testament to the lived experience shared by patients and caregivers that helped to shape that understanding, and sets a strong foundation for our continued efforts to bring access to much needed new treatment options”.
Alexion are working on their next steps and will share an update on timings with us as soon as possible. They would also like to invite the community to join a webinar on Friday 11 October to share the PBAC outcomes in greater detail, address community concerns, and update on their continued efforts to advocate for timely and equitable access in Mg.
More information will be shared regarding the webinar as it comes to hand.
